# Vyome Holdings, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Vyome Holdings, Inc). ## Overview Vyome Holdings, Inc. is a U.S.-based clinical-stage specialty pharmaceutical company organized around a biotechnology pipeline and a legacy pharmaceutical products business. Its development programs focus on immune-inflammatory and rare diseases, including topical and ophthalmic candidates, while the pharmaceutical segment includes antifungal products and related licensing arrangements. ## Products & services • VT-1953 topical gel for malignant fungating wounds • VT-1908 ophthalmic drops for steroid-sparing anterior uveitis • VB-1953 acne program, Phase 3-ready • Antifungal pharmaceutical products • Licensing arrangements tied to legacy pharma assets - **Biotechnology pipeline** (0%) — Clinical and preclinical drug candidates for immune-inflammatory and rare diseases. - **Pharmaceutical products** (100%) — Legacy antifungal products and related commercial pharmaceutical operations. - **Licensing and collaboration rights** (0%) — Legacy licensing agreements and potential partnering arrangements around assets. - VT-1953 topical gel for malignant fungating wounds - VT-1908 ophthalmic drops for steroid-sparing anterior uveitis - VB-1953 acne program, Phase 3-ready - Antifungal pharmaceutical products - Licensing arrangements tied to legacy pharma assets ## Customers The company’s biotechnology programs are aimed at patients with serious unmet medical needs, typically accessed through physicians, specialists, and clinical trial sites rather than direct consumer channels. Its pharmaceutical segment serves healthcare providers and patients through antifungal products, with commercialization shaped by licensing relationships and specialty prescribing patterns. - **Specialty physicians and patients** (primary) — They use the pipeline therapies for rare, inflammatory, or dermatologic conditions where current options are limited. - **Healthcare providers** (primary) — They prescribe the antifungal products and influence adoption through treatment protocols. - **Clinical trial ecosystem** (primary) — Investigators, sites, and enrolled patients support development of VT-1953, VT-1908, and VB-1953. - **Licensing counterparties** (secondary) — Partners such as Sun Pharma-related arrangements support legacy pharmaceutical economics. - Patients with malignant fungating wounds treated through oncology care - Ophthalmology patients with anterior uveitis - Dermatology patients with moderate to severe acne - Healthcare providers prescribing antifungal products - Clinical investigators and trial sites supporting development programs ## Geography Vyome Holdings is based in the United States, with a reported operating footprint spanning Cambridge, Massachusetts, Princeton, New Jersey, and New Delhi, India. The U.S.-India structure matters because the company combines U.S.-based clinical and corporate functions with Indian innovation and development capabilities. - Headquartered in the United States - Operations in Cambridge, MA and Princeton, NJ - Development presence in New Delhi, India - U.S.-India innovation corridor supports R&D execution - Geography is operational, not revenue-disclosed in the filing ## Strategy The company’s strategy centers on advancing its lead clinical and preclinical programs toward regulatory milestones while preserving access to external capital. It also seeks to use collaborations, licensing, and financing tools to support development of its pipeline and legacy pharmaceutical assets. - **Advance VT-1953 into pivotal development** (short-term) — This is the lead program and the most advanced path to a potential commercial asset. - **Progress the ophthalmology and acne pipeline** (medium-term) — Diversifies the pipeline across multiple specialty indications and reduces single-asset dependence. - **Secure external funding and partnerships** (short-term) — Clinical development requires capital and the company expects to rely on financing and collaborations. - Advance VT-1953 toward pivotal trial discussions with FDA - Progress VT-1908 through pre-IND development - Move VB-1953 toward Phase 3 development - Use equity, debt, and partnerships to fund R&D - Leverage licensing and collaboration opportunities ## Risks Vyome’s business depends on successful clinical development, regulatory clearance, and the ability to finance a pipeline that has no approved biotechnology products. The company also faces execution risk from its dual-segment structure, where legacy pharmaceutical revenue is separate from development spending, and from the uncertainty of raising capital on acceptable terms. - **Clinical development failure or delay** [high] — Pipeline value depends on positive preclinical and clinical results and timely advancement. - **Capital raising and liquidity risk** [high] — The company expects to fund operations through equity, debt, and collaborations until product revenue exists. - **Regulatory risk** [high] — Drug development requires FDA alignment on protocols, approvals, and labeling. - **Commercialization risk in legacy pharma** [medium] — Antifungal products and licensing arrangements may not generate enough scale to support the business. - No approved biotech products yet, so development success is uncertain - Clinical trials may be delayed, fail, or require more capital than planned - Regulatory outcomes depend on FDA review and trial design acceptance - Funding risk is elevated because operations rely on external capital - Legacy pharma economics may not offset biotech development spending ## Accounting The most important accounting issues are fair value accounting for convertible promissory notes and other financing instruments, which can create non-cash earnings volatility. Investors should also watch stock-based compensation, merger-related transaction accounting, and any impairment or valuation judgments tied to development-stage assets and legacy pharmaceutical rights. - **Convertible promissory notes at fair value** — Non-cash income or expense volatility - **Derivative accounting for embedded features** — Can materially affect reported results period to period - **Stock-based compensation** — Dilution and expense recognition - **Business combination and merger accounting** — Affects balance sheet and comparability - Convertible notes may be measured at fair value through earnings - Derivative features can create non-cash gains or losses - Stock-based compensation affects reported operating expense - Merger and private placement accounting can affect equity balances - Development-stage asset valuation may require impairment judgments --- *Last updated: 2026-04-29T05:08:47.983499+00:00*